Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 184 for “"CRPC"”.

  1. GRB10 as a key regulator contributing to the development of castration-resistant prostate cancer

    … recurrent castration-resistant prostate cancer (CRPC) commonly occur. Current therapies for CRPC, e.g. next-generation ADT including Enzalutamide and Abiraterone, can extend patients’ lives but are not curative as resistance to their use eventually emerges. As such, there is an urgent need to …

    ubc Repository record for GRB10 as a key regulator contributing to the development of castration-resistant prostate cancer (opens in a new tab) Download PDF for GRB10 as a key regulator contributing to the development of castration-resistant prostate cancer (opens in a new tab)

  2. Phenotypes and transcriptional regulators of non-luminal epithelial cell identities in castration-resistant prostate cancer.

    … develop castration-resistant prostate cancer (CRPC). Targeted therapies can promote lineage plasticity, which is defined as the ability of a cell to alter its identity in response to external pressures. While 70-75% of CRPC restores AR signaling, the remaining 25-30% display lineage plasticity …

    umn Repository record for Phenotypes and transcriptional regulators of non-luminal epithelial cell identities in castration-resistant prostate cancer. (opens in a new tab)

  3. Tmprss2-Erg Regulation Of Androgen Biosynthetic Enzyme Expression, Dht Synthesis, And Androgen Receptor Activation In Prostate Cancer

    … of castration-resistant prostate cancer (CRPC). Several enzymes responsible for androgen biosynthesis have been shown to be overexpressed in CRPC, thus, contributing to CRPC in a castrated environment. Although intratumoral androgen synthesis is thought to contribute to the development and …

    wayne-thes Repository record for Tmprss2-Erg Regulation Of Androgen Biosynthetic Enzyme Expression, Dht Synthesis, And Androgen Receptor Activation In Prostate Cancer (opens in a new tab)

  4. PORCUPINE’S ROLE IN THE ENHANCEMENT OF ENZALUTAMIDE EFFICACY IN DRUG RESISTANT PROSTATE CANCER

    … of castration-resistant prostate cancer (CRPC). Subsequently, this has led to the development of Androgen Signaling Inhibitors (ASI), specifically Enzalutamide (ENZ), which is a direct inhibitor of AR, to clinically manage CRPC. Inevitably, ENZ treatment only provides improvement for …

    uky-thes Repository record for PORCUPINE’S ROLE IN THE ENHANCEMENT OF ENZALUTAMIDE EFFICACY IN DRUG RESISTANT PROSTATE CANCER (opens in a new tab)

  5. Utilizing catalytic Topo II inhibitor to target reestablished androgen receptor signaling in castration-resistant prostate cancer

    … the lethal castration-resistant prostate cancer (CRPC) stage. Defining the mechanisms that promote the reestablishment of AR signaling including the androgen independence is important for therapy development and disease control. UDP-glucuronosyltransferase 2B17 (UGT2B17) is a key enzyme that …

    ubc Repository record for Utilizing catalytic Topo II inhibitor to target reestablished androgen receptor signaling in castration-resistant prostate cancer (opens in a new tab) Download PDF for Utilizing catalytic Topo II inhibitor to target reestablished androgen receptor signaling in castration-resistant prostate cancer (opens in a new tab)

  6. TMEFF2 is an epigenetic modulator that promotes androgen independent growth in castration-resistant prostate cancer cells

    … castration resistant prostate cancer (CRPC), during which the PCa cells develop the ability to grow in androgen depleted conditions. The androgen receptor (AR) plays a vital role in prostate development and homeostasis, and the deregulation of AR drives PCa tumorigenesis and progression …

    ecu Repository record for TMEFF2 is an epigenetic modulator that promotes androgen independent growth in castration-resistant prostate cancer cells (opens in a new tab)

  7. Beyond Inhibition: Overcoming the Kinase-Independent Functions of PIM1 by Targeted Degradation

    … to castration-resistant prostate cancer (CRPC). CRPC is a highly aggressive form of cancer, and the five-year survival rate for CRPC patients is dismal. Current treatment options for CRPC include chemotherapy and targeted agents, but these therapies have not been effective. Thus, new …

    arizona-thes Repository record for Beyond Inhibition: Overcoming the Kinase-Independent Functions of PIM1 by Targeted Degradation (opens in a new tab)

  8. Hsp60 Promotes Aggressive Prostate Cancer by Modulating Mitochondrial Function

    … to ADT and becomes castrate resistant (CRPC). The most aggressive subset of CRPC appears with altered or deleted tumor suppressors Rb1/p53, and as a result has low/no AR expression. This aggressive phenotype readily metastasizes, displays resistance to chemotherapeutic agents and absence …

    buffalo Repository record for Hsp60 Promotes Aggressive Prostate Cancer by Modulating Mitochondrial Function (opens in a new tab)

  9. Genetic Aberrations And Cholesterol Metabolism In Castration-Resistant Prostate Cancer

    … of the disease, termed castration-resistant PCa (CRPC), accounts for most PCa mortality. PCa is initially dependent on androgens and androgen receptor signaling (AR) for its growth and proliferation. Hence, most therapies for metastatic PCa are directed at inhibiting this signaling axis through …

    umn Repository record for Genetic Aberrations And Cholesterol Metabolism In Castration-Resistant Prostate Cancer (opens in a new tab)

  10. Macrophages promotion of anti-androgen resistance and lineage plasticity in prostate cancer

    … of castration-resistant prostate cancer (CRPC). Lineage plasticity has been identified as a crucial mechanism to promote CRPC. Here we identify macrophages secreted factors drives castration-resistance and promotes lineage plasticity. These factors increased the resistance of PC cells …

    edinburgh Repository record for Macrophages promotion of anti-androgen resistance and lineage plasticity in prostate cancer (opens in a new tab)

  11. Dual Inhibition of ATR and DNA-PKcs Radiosensitizes ATM Mutant Prostate Cancer

    In advanced castration resistant prostate cancer (CRPC), mutations in the DNA damage response (DDR) gene ataxia telangiectasia mutated (ATM) are common. While poly (ADP-ribose) polymerase inhibitors are approved in this context, their clinical efficacy remains limited. Thus, there is a compelling …

    utswmed Repository record for Dual Inhibition of ATR and DNA-PKcs Radiosensitizes ATM Mutant Prostate Cancer (opens in a new tab)

  12. Preclinical Development and Mechanistic Studies of miR-34a to Target Aggressive Prostate Cancer

    … in its aggressive, castration-resistant form (CRPC), presents a significant clinical challenge due to its resistance to conventional therapies. The heterogeneity of CRPC, characterized by varying androgen receptor (AR) expression and the presence of prostate cancer stem cells (PCSCs), further …

    buffalo Repository record for Preclinical Development and Mechanistic Studies of miR-34a to Target Aggressive Prostate Cancer (opens in a new tab)

  13. The Mechanistic Role of Long Non-coding RNAs in Advanced Prostate Cancer Response to Therapy

    … called Castration-Resistant Prostate Cancers (CRPCs). Therapies currently used for CRPC treatment include: the new generation anti-androgen enzalutamide, the taxane cabazitaxel and carboplatin. Despite the prolonged survival resulting from these treatments, CRPC is still incurable. Recent …

    the-open-u Download PDF for The Mechanistic Role of Long Non-coding RNAs in Advanced Prostate Cancer Response to Therapy (opens in a new tab)

  14. CDK8 AND CDK19 Mediator Kinases as Novel Targets in Advanced Prostate Cancer

    … to castration resistant prostate cancer (CRPC) status, where their growth becomes independent of androgen signaling, through altered androgen receptor (AR) signaling or other genetic or transcriptional changes. Metastatic CRPC remains incurable, and the most potent new drugs prolong …

    south-carolina Repository record for CDK8 AND CDK19 Mediator Kinases as Novel Targets in Advanced Prostate Cancer (opens in a new tab)

  15. A lifestyle intervention to improve outcomes in men with castrate-resistant prostate cancer

    … in men with castrate resistant prostate cancer (CRPC), the terminal phase of the disease. It is not clear how exercise has been implemented in the prostate cancer care pathway and what a successfully implemented exercise programme might look like. Furthermore, the specific treatment and disease …

    sheffield-hallam Repository record for A lifestyle intervention to improve outcomes in men with castrate-resistant prostate cancer (opens in a new tab) Download PDF for A lifestyle intervention to improve outcomes in men with castrate-resistant prostate cancer (opens in a new tab)

  16. Characterisation and role of SLFN5 in castration resistant prostate cancer

    Castration resistant prostate cancer (CRPC) is a currently incurable form of prostate cancer. While varying in different countries, prostate cancer recurrence typically manifests clinically around 12-24 months after androgen deprivation therapy, signifying disease treatment resistance1. Tumour …

    glasgow Repository record for Characterisation and role of SLFN5 in castration resistant prostate cancer (opens in a new tab) Download PDF for Characterisation and role of SLFN5 in castration resistant prostate cancer (opens in a new tab)

  17. Computational drug discovery for advanced prostate cancers

    … to castration-resistant prostate cancer (CRPC), a lethal subtype that displays universal resistance to standard-of-care (SOC) therapies. Given the current lack of efficacious treatments, survival among CRPC patients remains poor. Therefore, there is an urgent need to develop new treatment …

    umn Repository record for Computational drug discovery for advanced prostate cancers (opens in a new tab)

Page 1 of 10